(0.00%) 5 478.75 points
(-0.01%) 38 814 points
(0.05%) 19 930 points
(0.26%) $80.54
(0.86%) $2.81
(0.12%) $2 331.90
(-0.31%) $29.30
(-0.02%) $970.70
(0.03%) $0.932
(-0.10%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases...
Stats | |
---|---|
Šios dienos apimtis | 960 928 |
Vidutinė apimtis | 0 |
Rinkos kapitalizacija | 0.00 |
EPS | $0.0766 ( Q2 | 2022-08-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
47.62 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.137 (2.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-22 | Rosen Robert | Sell | 30 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 18 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 11 680 911 |
Tūris Koreliacija
La Jolla Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
La Jolla Pharmaceutical Koreliacija - Valiuta/Žaliavos
La Jolla Pharmaceutical Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $75.72M |
Bruto pelnas: | $62.23M (82.19 %) |
EPS: | $0.720 |
FY | 2021 |
Pajamos: | $75.72M |
Bruto pelnas: | $62.23M (82.19 %) |
EPS: | $0.720 |
FY | 2020 |
Pajamos: | $33.42M |
Bruto pelnas: | $25.60M (76.60 %) |
EPS: | $-1.440 |
FY | 2019 |
Pajamos: | $23.05M |
Bruto pelnas: | $20.66M (89.62 %) |
EPS: | $-4.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
La Jolla Pharmaceutical
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.